CARDIOVASCULAR JOURNAL OF AFRICA • SMC-PAFCIC Abstracts October 2022 43 AFRICA Submission ID: 1582 TOXIC CARDIOMYOPATHY DUE TO TRASTUZUMAB’S USE IN BREAST CANCER PATIENTS IN THE CARDIO-ONCOLOGY UNIT OF CASABLANCA MAAROUFI ANASS, ABOURICHE AMIRA, BENDAHOU HAJAR, BELKOUCHIA SAMI, HABOUB MERIEM, AROUS SALIM, BENOUNA EL GHALI, AZZOUZI LEILA, HABBAL RACHIDA, TAWFIK NEZHA MOROCCO Introduction: Trastuzumab has led to a significant improvement in the treatment of both advanced and early breast cancer that over-expresses HER2 receptors. However, it is associated with an important cardiotoxicity that requires a systematic monitoring of left ventricular ejection fraction (LVEF) before and during the treatment. We present our experience with patients who developed trastuzumab-related cardiotoxicity. Purpose: To evaluate the incidence and the reversibility toxic cardiomyopathy induced by trastuzumab in our cardio-oncology unit. Methods: We conducted a prospective observational study from January 2017 to June 2022 in the cardio-oncology unit of Casablanca, Morocco. Results: 1583 patients were included. The average LVEF before initiation of trastuzumab was 59,9±11,2% and 51,9±6.6% at the end of treatment. A decreased LVEF was detected in 58 patients (3.6%), symptomatic in 30 cases, asymptomatic in 28 patients. Cardiotoxicity occured for a mean cumulative dose > 40mg/ m2. During the follow-up, 48 patients (82.7%) had a retrieval of their LVEF after a mean period of 6.4 months after trastuzumab termination. 10 cases of TIC were irreversible despite an optimal cardioprotective therapy. Conclusion: Patients who develop toxic cardiomyopathy generally improve their LVEF on removal of the agent and after initiation of cardioprotective therapy. The clinical outcome is more favorable than anthracycline cardiotoxicity. This reversibility is usually observed in early identified patients, showing the importance of a systematic monitoring of LV function before, during and after the treatment. Submission ID: 1583 THE IMPACT OF OVERWEIGHT IN LEFT ATRIAL AND LEFT VENTRICULAR STRUCTURE AND FUNCTION IN HYPERTENSIVE PATIENTS MARWA ABDELHEDI, SARRA CHENIK, AYMEN NOAMEN, TAHA YASSINE JABLOUN, ABDEDDAYEM HAGGUI, WAFA FEHRI TUNISIA Background: Obesity and hypertension are both associated with abnormalities in cardiac remodeling and high risk of heart failure (HF) Therefore, it is important to highlight the further deterioration of left atrial (LA) and left ventricular (LV) function in hypertensive patients with overweight. The purpose of the present study was to examine the contribution of overweight to left atrial (LA) and left ventricular (LV) dysfunction in hypertensive patients. Methods: This cross-sectional prospective study included 60 hypertensive patients who underwent complete 2D echocardiography examination. Patients was classified into two subgroups according to their body mass index (BMI): non overweight patients (n=15, BMI<25kg/m²) and patients with overweight (n=45, BMI ≥25 Kg/m²). The LV wall thicknesses, different diameters, left ventricular mass index (LVM) and relative wall thickness (RWT) were assessed by M-mode. LV end-diastolic volume (EDV), end-systolic volume (ESV) and Left ventricular ejection fraction (LVEF) were calculated from the apical two- and four-chamber views using Simpson’s method. The LA volume (LAV) was measured offline using the biplane area-length method, and was indexed to the body surface area. Speckle-tracking strain analyses of the LV and LA were performed: We acquired LV short-axis views at the apical, mid and basal levels, and LV apical two, three and four-chamber views. Mean values of LA Strain corresponding to three phases of atrial function: reservoir (PALS), conduit and contraction (PACS), were obtained from the apical two- and four-chamber views. Results: The LV wall thicknesses, RWT, and LVM index of the overweight group were greater compared with the non-overweight group with p=0,02 p=0.36 and p=0.06 respectively. There were no differences in LVEF, ESV and LAV index between the two groups. Only EDV was greater in the overweight group with a significant difference (p=0.002). The LV longitudinal strain was lower in the overweight group (p=0.42). However, there was no difference in LV circumferential strain. PALS was lower in overweight group with p=0.08. No significance difference is obtained with conduct and contraction between the two groups. Conclusion: These results suggest that LA and LV dysfunction, are aggravated with overweight in hypertensive patients probably leading to the elevated LV filling pressure and development to heart failure with preserved ejection fraction in future. Submission ID: 1588 THE IMPACT OF PRIOR ANTITHROMBOTIC USE ON THROMBOEMBOLIC EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE AND SEVERE COVID-19 INFECTION AMINE BOUCHLARHEM, NABILA ISMAILI, NOHA EL OUAFI MOROCCO Objective: Our objective in this study is to determine the predictive factors of thromboembolic complications in patients with previous heart disease and severe covid-19 infection and the impact of previous use of antithrombotic drugs on protection against these complications. Methods: We conducted a single-center retrospective study of 158 patients with heart disease admitted to an intensive care unit for severe SARS-COV-2 infection. To determine the predictive factors, we used a logistic regression analysis. Results: Out of 158 patients, 22 were complicated by a thromboembolic event, i.e. 13.9%, mean age of our population was 64.03 (SD = 15.27), with a male predominance of 98 (62%), For the predictive factors of thromboembolic complications, and after multivariate analysis, we find the duration of hospitalization with (OR=0.92 ; 95%CI (0.863 - 0.983), p=0.014, previous use of anti-thrombotic drugs as a protective factor with ( OR=0.288, 95%CI (0.091 - 0.911), p=0.034 for anti-platelet agents ) and ( OR=0, 322, 95%CI (0.131 - 0.851), p=0.021) for anti-coagulants (Figure1), and finally thrombocytopenia at admission as a risk factor ( OR=4.58 95%CI MODERATED POSTER SESSION
RkJQdWJsaXNoZXIy NDIzNzc=